Archive · 24 Aug 2026
India Tightens Sale Rules for Four CNS Drugs
India wants to make it harder to sell four medicines without careful records.
The medicines are flupentixol, zopiclone, gabapentin and carisoprodol.
They are used for conditions including schizophrenia, insomnia, nerve pain and muscle problems.
The government is concerned that some people may misuse them to become intoxicated.
If the proposal takes effect, pharmacies will need to write down who received the medicine.
They must also record the doctor who prescribed it and how much was supplied.
These records must be kept for three years.
The rules are not final yet because people and organisations have 30 days to give feedback.
The Health Ministry has proposed placing flupentixol, zopiclone, gabapentin and carisoprodol under Schedule H1.
Pharmacies would have to record patient, prescribing-doctor and quantity details for every sale of these medicines.
Sales records must be preserved for three years and made available for inspection by authorities.
The notification is dated August 19 and will be finalised after a 30-day period for stakeholder feedback.
The move follows concerns about misuse and intoxication, and comes after similar restrictions on pregabalin.
- Who
- India’s Ministry of Health and Family Welfare, following recommendations involving the Drugs Consultative Committee and an expert committee.
- What
- The government has proposed adding flupentixol, zopiclone, gabapentin and carisoprodol to Schedule H1, imposing stricter sales-record requirements.
- When
- The notification is dated August 19; stakeholders have 30 days to provide feedback before finalisation.
- Where
- India.
- Why
- Expert bodies raised concerns that the four central nervous system medicines could be misused for intoxication.
- Medicines affected
- Flupentixol, zopiclone, gabapentin and carisoprodol
- Proposed classification
- Schedule H1 under the Drugs and Cosmetics Act
- Required records
- Patient details, prescribing doctor’s name and address, and quantity supplied
- Record-retention period
- Three years
- Feedback period
- 30 days before the notification is finalised
- Recommendation timing
- The Drugs Consultative Committee recommended the change five months earlier
- CNS medicine sales
- The segment recorded Rs 17,439 crore in moving annual turnover from August 2025 to July 2026